BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting

BOSTON, April 18, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced five poster presentations showing new promising preclinical pancreatic cancer data, including new biomarkers for detection and improved treatment outcomes via the combination of BPM31510 with gemcitabine. Additionally new data demonstrates molecular drivers of endothelial cell (EC) angiogenic response to hypoxia, and its effects. The research was guided by BERG’s Interrogative Biology ® Platform. The data is being presented at the American Association for Cancer Research (AACR) Annual Meeting, being held April 16-20, 2016 in New Orleans, LA.

“These findings provide new evidence supporting the potential of BPM31510 to battle some of the most deadly cancers, including highly metabolic tumors, and improve treatment outcomes,” said Niven R. Narain, co-founder, president and chief executive officer of BERG. “Using our Interrogative Biology® platform, our goal is to treat patients with therapies that match the biology of their disease. This new data further supports the promise of our precision medicine approach to drug development and we look forward to advancing BPM31510 into phase II trials in cancers where there is a huge unmet need.

The five abstract titles include:

  • BPM31510 synergizes gemcitabine efficacy in pancreatic adenocarcinoma via mechanism independent of its anti-Warburg influence on metabolism.
  • BPM31510-induced alteration in Complex II activity is functionally linked to cell death activation pathway in a preclinical model of triple-negative breast cancer.
  • Project Survival: Interrogative Biology® platform mediated discovery of molecular markers for detection, stratification and outcomes in pancreatic cancer.
  • The anti-Warburg agent BPM31510 arbitrates fatty acid metabolism in eliciting an anticancer response.
  • Molecular drivers of endothelial hypoxic adaption during angiogenesis deciphered using the Berg Interrogative Biology® platform.

BERG, the namesake of Chairman and Co-founder Carl E. Berg, utilizes artificial intelligence as a foundation to creating the next generation of drugs and diagnostics. Its revolutionary drug, BPM31510, is one of the first cancer drugs guided in development by artificial intelligence. It works by reprogramming the metabolism of cancer cells, or reversing the Warburg effect, re-teaching them to undergo cell death. Data from preclinical and human trials indicate that treatment with BPM31510 as a single-agent leads to tumor regression and clinical benefits and increases antitumor activity in combination with chemotherapy agents.

BERG’s Interrogative Biology® Platform looks at patients by “phenotype” rather than “genotype” by integrating molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide physicians with actionable data to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary, and governments with a data ecosystem for financial modeling of healthcare needs of the population

Full abstracts of the posters are available on the AACR website.

About BERG
BERG, is a biopharmaceutical company with divisions that include Analytics, Pharma, Biosystems and Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, please visit www.berghealth.com.

About the BERG Interrogative Biology™ Platform
BERG’s application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The BERG Interrogative Biology® platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population